Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.
Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.
复制标题
DOI：
10.1002/art.24803
复制
发表时间：
2009-10
影响因子：
--
通讯作者：
Baechler, Emily C.
中科院分区：
文献类型：
--
作者：
Bauer, Jason W.;Petri, Michelle;Batliwalla, Franak M.;Koeuth, Thearith;Wilson, Joseph;Slattery, Catherine;Panoskaltsis-Mortari, Angela;Gregersen, Peter K.;Behrens, Timothy W.;Baechler, Emily C.
系统性红斑狼疮（SLE）是一种复杂的自身免疫性疾病，其特征是不可预测的疾病活动和不可逆的损害多器官系统。早期的研究表明，血液中携带干扰素基因表达特征的SLE患者血清中干扰素（IFN）调节的趋化因子水平升高。这些趋化因子与更严重和活跃的疾病相关，并显示出作为SLE疾病活动生物标志物的前景。本研究旨在验证干扰素调节的趋化因子作为267名纵向随访的系统性红斑狼疮患者的系统性红斑狼疮疾病活动性生物标志物。为了验证血清趋化因子水平作为疾病活动性生物标志物的潜在效用，我们在一个独立队列中测量了267例SLE患者的血清趋化因子水平-CXCL 10（IP-10），CCL 2（MCP-1）和CCL 19（MIP-3B）-纵向随访超过一年（共1166次访视）。血清趋化因子水平与当前访问狼疮活动相关（p=2×10−10），在发作时升高（p=1×10−3），随着疾病缓解而降低（p=1×10− 3），并且比目前可用的实验室检查更好。在SLEDAI ≤4的患者中，在一次基线访视时测量的趋化因子水平可预测随后一年内的狼疮发作（p=6×10−4）。监测SLE患者血清趋化因子水平可改善当前疾病活动性的评估、未来复发的预测和总体临床决策。
Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by unpredictable flares of disease activity and irreversible damage to multiple organ systems. An earlier study showed that SLE patients carrying an interferon gene expression signature in blood have elevated serum levels of interferon (IFN)-regulated chemokines. These chemokines were associated with more severe and active disease and showed promise as SLE disease activity biomarkers. This study was designed to validate IFN regulated chemokines as biomarkers of SLE disease activity in 267 longitudinally-followed SLE patients. To validate the potential utility of serum chemokine levels as biomarkers for disease activity, we measured serum chemokine levels – CXCL10 (IP-10), CCL2 (MCP-1), and CCL19 (MIP-3B) – in an independent cohort of 267 SLE patients followed longitudinally over one year (1166 total visits). Serum chemokine levels correlated with current visit lupus activity (p=2×10−10), rising at flare (p=1×10−3) and decreasing as disease remitted (p=1×10−3), and performed better than currently available laboratory tests. Chemokine levels measured at a single baseline visit in patients with SLEDAI ≤4 were predictive of lupus flare over the ensuing year (p=6×10−4). Monitoring serum chemokine levels in SLE may improve assessment of current disease activity, the prediction of future flare, and overall clinical decision-making.
登录
查看更多内容
影响因子：
27.4
作者：
SWAAK, AJG;GROENWOLD, J;BRONSVELD, W
通讯作者：
BRONSVELD, W
影响因子：
--
作者：
Meller, S;Winterberg, F;Homey, B
通讯作者：
Homey, B
影响因子：
--
作者：
PETRI, M;GENOVESE, M;HOCHBERG, M
通讯作者：
HOCHBERG, M
影响因子：
3.4
作者：
Vila, Luis M.;Molina, Maria J.;Rios, Zilka
通讯作者：
Rios, Zilka
DOI：
10.1084/jem.20021553
发表时间：
2003-03-17
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Bennett L;Palucka AK;Arce E;Cantrell V;Borvak J;Banchereau J;Pascual V
通讯作者：
Pascual V